Therma Bright building nice portfolio for M&ANext up.... will probably be an extension into other saliva-based, mouht-borne disease tests, as I have shared before. Lock this one down, prove its success, and then produce other saliva tests around gum disease, throat and lung cancer, thyroid, diabetes and other diseases and ailments.
AcuVid might be a ground breaker on Covid-19 Rapid Antigen Tests...shifting from nasal-to-mouth detection, but its the tip of the iceburg in the entire health detection space. And THRM, with their partners, not oly have the experience now, but the where with all with $6M in bank and another $7.5M coming from 20M Warrants at $0.375... a mere dime away.
That is what HC Wainright team sees Therma as...an a solid M&A candidate that they will get paid multiple times on. 20M in stock payout with FDA EUA pop, 20M Warrant payout with FDA EUA, and then the shift to M&A payout with an acquirer who see beyond Covid19 salaiva detection. Easier to buy a company with expeirence in this space, then spend $$$ dollars in R&D, and shareholder frustration. "Let others build it for us, and then we will come and take them over." That's the play